Abstract: The present disclosure provides compositions and methods comprising spherical nucleic acid (SNA) components for use as immunotherapeutic agents. The disclosure provides a method comprising: treating a population of antigen presenting cells with a SNA comprising a nanoparticle, an antigen, and an adjuvant; and determining a time at which the population of antigen presenting cells presents a maximal signal that is indicative of antigen presentation by the antigen presenting cells and a time at which the population of antigen presenting cells presents a maximal co-stimulatory signal due to the adjuvant. The disclosure includes compositions that comprise a pharmaceutically acceptable carrier and a SNA of the disclosure, wherein the SNA comprises a nanoparticle, an oligonucleotide on the surface of the nanoparticle, and an antigen that is associated with the surface of the SNA via a linker. The disclosure additionally includes articles of manufacture and kits.

Abstract: Provided is a fusion protein of insulin and an immunoglobulin Fc region. Specifically, the present invention relates to an insulin fusion protein having a prolonged in vivo half-life and stability, a preparation that contains the fusion protein, a preparation method therefor and an application thereof.

Abstract: The present disclosure is generally directed to spherical nucleic acids (SNAs) comprising multiple TLR agonists that enable the simultaneous activation of multiple TLR pathways for maximally synergistic immune activation. In some aspects, the present disclosure provides a spherical nucleic acid (SNA) comprising: (a) a nanoparticle core; (b) one or more toll-like receptor 3 (TLR3) agonists encapsulated in the nanoparticle core; and (c) a shell of oligonucleotides attached to the external surface of the nanoparticle core, the shell of oligonucleotides comprising one or more toll-like receptor 9 (TLR9) agonist oligonucleotides. Methods of using the SNAs are also provided herein.

Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Abstract: Disclosed are a coagulation factor VIII fusion protein which is conjugated with polyalkylene glycol and which has an extended cyclic half-life, a preparation method therefor and a use thereof, wherein the active moiety of the coagulation factor VIII is directly linked or indirectly linked by a peptide linker to a fusion partner, and the fusion protein is further conjugated to a polyalkylene glycol. The half-life is significantly increased compared to an FVIII fusion protein modified without polyalkylene glycol.

Abstract: The disclosure is generally directed to immunostimulatory protein-core spherical nucleic acids (SNAs) comprising a protein core and a ratio of immunostimulatory and non-immunostimulatory strands, methods of making the immunostimulatory protein-core SNAs as well as their use.

Abstract: The present disclosure provides compositions and methods comprising spherical nucleic acid (SNA) components for use as immunotherapeutic agents. The disclosure provides a method comprising: treating a population of antigen presenting cells with a SNA comprising a nanoparticle, an antigen, and an adjuvant; and determining a time at which the population of antigen presenting cells presents a maximal signal that is indicative of antigen presentation by the antigen presenting cells and a time at which the population of antigen presenting cells presents a maximal co-stimulatory signal due to the adjuvant. The disclosure includes compositions that comprise a pharmaceutically acceptable carrier and a SNA of the disclosure, wherein the SNA comprises a nanoparticle, an oligonucleotide on the surface of the nanoparticle, and an antigen that is associated with the surface of the SNA via a linker. The disclosure additionally includes articles of manufacture and kits.

Abstract: The present disclosure provides compositions and methods directed to combining spherical nucleic acid (SNA) components that are required for T-cell activation and proliferation.

Abstract: A highly glycosylated human blood-clotting factor VIII (FVIII) fusion protein, and a manufacturing method and application of same. The fusion protein comprises, from the N-terminus to the C-terminus, a human (FVIII), a flexible peptide connector, at least one rigid unit of a human chorionic gonadotropin ?-subunit carboxyl terminal peptide, and a half-life extending portion (preferentially selected from a human IgG Fc variant). The fusion protein has a similar level of biological activity as a recombinant (FVIII) and an extended in vivo half-life, thereby improving pharmacokinetics and drug efficacy.

Abstract: The use of lidocaine or other Class I cardiac antiarrhythmic compound in the management of preterm labor and the stoppage of labor preparatory to cesarian delivery, is disclosed. The electrophysiological effects of lidocaine on the sodium, calcium and potassium channels of freshly dissociated myocytes from late-pregnant rat uteri with the tight-seal patch-clamp method are presented. Dose-response relations on the sodium and calcium currents, and effects on the availability relation for sodium current are also presented. Also disclosed are the effects of chronic administration of lidocaine on the duration of pregnancy.